On June 28, 2021 Novartis reported it dutifully shelled out tens of millions to Genentech as part of a patent licensing deal that dated back to 2005 (Press release, Novartis, JUN 28, 2021, View Source [SID1234584562]). Later, the Swiss pharma discovered it accidentally overpaid by nearly $210 million
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Those are the central arguments in a lawsuit filed by Novartis against its Swiss pharma counterpart seeking $209.5 million. In the suit, which recently made its way to California federal court, Novartis says Genentech isn’t coughing up the dough.
Novartis claims Genentech was aware, or at least should’ve known, that the company was overpaying the entire time.
EXECUTIVE SUMMARY DOWNLOAD
Are Real-time Gene Therapy Results Possible?
As science and technology companies continue to make advancements in vaccine and viral vector-based gene therapy development, there is an increasing need for analytical techniques that can help assess quality parameters, especially in real-time. In a step toward process improvements, Catalent recently partnered with LumaCyte’s Laser Force Cytology (LFC) instrument, Radiance, to apply more rapid and accurate measurement of quality attributes—such as viral titer and infectivity—to cell testing. Download for free.
LEARN MORE
The payments stemmed from a 2005 licensing agreement Genentech struck with then Chiron Corporation related to its antibody patents. Novartis picked up Chiron a year later and developed several commercial antibody products from the pact, notably immunology meds Ilaris and Cosentyx, the suit says.
RELATED: Novartis hits setback in bid to block Regeneron’s Eylea prefilled syringe as dual lawsuits drag on
Instead of alerting Novartis of the overpayments, Genentech continued to "seek, accept, and retain" the funds driven by Ilaris and Cosentyx sales, even though they weren’t entitled to them, Novartis argued in the filing.
While terms of the initial licensing deal weren’t disclosed, Novartis maintains it "performed all or substantially all of its obligations" under the deal and later learned of the overpayments after it expired.
Meanwhile, lawyers representing Genentech dismissed Novartis’ claims in a filing seeking to move the case from state to federal court, arguing the claims fall under federal patent law.
The companies weren’t immediately available for comment.
RELATED: Novartis’ closely watched canakinumab hits a snag in lung cancer. What’s next for the anti-inflammatory drug?
Cosentyx, which first launched in 2015, directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyloarthritis.
The treatment has become Novartis’ largest brand, driving $3.9 billion in sales last year, up 13% compared with the year prior.
Meanwhile, sales of IL-1beta inhibitor Ilaris came in at roughly $873 million, up 30%. Despite efforts to push the medicine, also known as canakinumab, into fields outside immunology, Novartis has run into multiple setbacks, including in heart disease, COVID-19 and, most recently, non-small cell lung cancer.